iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35120619.
- Also identified by DOI 10.1016/j.stem.2022.01.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC) technology in 2007, and the scope of its application has been expanding. In addition to the development of cell therapies using iPSC-derived cells, pathological analyses using disease-specific iPSCs and clinical trials to confirm the safety and efficacy of drugs developed using iPSCs are progressing. With the innovation of related technologies, iPSC applications are about to enter a new stage. This review outlines advances in iPSC modeling and therapeutic development for cardinal neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson's disease, and Alzheimer's disease.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Induced Pluripotent Stem Cells
- Neurodegenerative Diseases